A citation-based method for searching scientific literature

Carol Aghajanian, Stephanie V Blank, Barbara A Goff, Patricia L Judson, Michael G Teneriello, Amreen Husain, Mika A Sovak, Jing Yi, Lawrence R Nycum. J Clin Oncol 2012
Times Cited: 788

Krishnansu S Tewari, Robert A Burger, Danielle Enserro, Barbara M Norquist, Elizabeth M Swisher, Mark F Brady, Michael A Bookman, Gini F Fleming, Helen Huang, Howard D Homesley, Jeffrey M Fowler, Benjamin E Greer, Matthew Boente, Sharon X Liang, Chenglin Ye, Carlos Bais, Leslie M Randall, John K Chan, J Stuart Ferriss, Robert L Coleman, Carol Aghajanian, Thomas J Herzog, Philip J DiSaia, Larry J Copeland, Robert S Mannel, Michael J Birrer, Bradley J Monk. J Clin Oncol 2019
Times Cited: 119

List of shared articles

Times cited

The use of bevacizumab in the modern era of targeted therapy for ovarian cancer: A systematic review and meta-analysis.
Shiru Liu, Lawrence Kasherman, Rouhi Fazelzad, Lisa Wang, Genevieve Bouchard-Fortier, Stephanie Lheureux, Monika K Krzyzanowska. Gynecol Oncol 2021

Poly(ADP-ribose) polymerase inhibitors in combination with anti-angiogenic agents for the treatment of advanced ovarian cancer.
Olivia Le Saux, Hélène Vanacker, Fatma Guermazi, Mélodie Carbonnaux, Clémence Roméo, Louis Larrouquère, Olivier Trédan, Isabelle Ray-Coquard. Future Oncol 2021

Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study.
Gennaro Daniele, Francesco Raspagliesi, Giovanni Scambia, Carmela Pisano, Nicoletta Colombo, Simona Frezzini, Germana Tognon, Grazia Artioli, Angiolo Gadducci, Rossella Lauria,[...]. Int J Gynecol Cancer 2021

The impact of body composition on treatment in ovarian cancer: a current insight.
Veronica McSharry, Kate Glennon, Amy Mullee, Donal Brennan. Expert Rev Clin Pharmacol 2021

Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
Angeles Alvarez Secord, David M O'Malley, Anil K Sood, Shannon N Westin, Joyce F Liu. Gynecol Oncol 2021

The Effects of Chemotherapeutics on the Ovarian Cancer Microenvironment.
Mark A Eckert, Carlos Orozco, Jason Xiao, Melissa Javellana, Ernst Lengyel. Cancers (Basel) 2021

Comprehensive Profiling of Hypoxia-Related miRNAs Identifies miR-23a-3p Overexpression as a Marker of Platinum Resistance and Poor Prognosis in High-Grade Serous Ovarian Cancer.
Paola Todeschini, Elisa Salviato, Chiara Romani, Vittoria Raimondi, Francesco Ciccarese, Federico Ferrari, Germana Tognon, Sergio Marchini, Maurizio D'Incalci, Laura Zanotti,[...]. Cancers (Basel) 2021

Comparisons of survival outcomes between bevacizumab and olaparib in BRCA-mutated, platinum-sensitive relapsed ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3052).
Se Ik Kim, Jeong-Won Lee, Kidong Kim, Maria Lee, Jigeun Yoo, Min Chul Choi, Suhyun Hwangbo, Young Hwa Kwak, Jong-Min Lee, So-Jin Shin,[...]. J Gynecol Oncol 2021

Cancer of the ovary, fallopian tube, and peritoneum: 2021 update.
Jonathan S Berek, Malte Renz, Sean Kehoe, Lalit Kumar, Michael Friedlander. Int J Gynaecol Obstet 2021

Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment.
Katherine C Kurnit, Gini F Fleming, Ernst Lengyel. Obstet Gynecol 2021

Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial.
J A Ledermann, A C Embleton-Thirsk, T J Perren, G C Jayson, G J S Rustin, S B Kaye, H Hirte, A Oza, M Vaughan, M Friedlander,[...]. ESMO Open 2021

Real-world experience of olaparib as maintenance therapy in BRCA-mutated recurrent ovarian cancer.
Angela Cho, Jeong-Yeol Park, Shin-Wha Lee, Dae-Yeon Kim, Dae-Shik Suh, Jong-Hyeok Kim, Yong-Man Kim, Young-Tak Kim. Arch Gynecol Obstet 2021

Bevacizumab in advanced endometrial cancer.
Maria M Rubinstein, Shannan Dickinson, Priyanka Narayan, Qin Zhou, Alexia Iasonos, Weining Ma, Yulia Lakhman, Vicky Makker. Gynecol Oncol 2021

Aglaja De Pauw, Eline Naert, Koen Van de Vijver, Tummers Philippe, Katrien Vandecasteele, Hannelore Denys. Acta Clin Belg 2021

AIM2 Inflammasome in Tumor Cells as a Biomarker for Predicting the Treatment Response to Antiangiogenic Therapy in Epithelial Ovarian Cancer Patients.
Po-Chao Hsu, Tai-Kuang Chao, Yu-Ching Chou, Mu-Hsien Yu, Yu-Chi Wang, Yi-Hsin Lin, Yi-Liang Lee, Li-Chun Liu, Cheng-Chang Chang. J Clin Med 2021

The role of vascular endothelial growth factor inhibitors in the treatment of epithelial ovarian cancer.
Alexander D Murphy, Robert D Morgan, Andrew R Clamp, Gordon C Jayson. Br J Cancer 2021

Latest clinical evidence of maintenance therapy in ovarian cancer.
Christine S Walsh. Curr Opin Obstet Gynecol 2020

Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook.
Josep Garcia, Herbert I Hurwitz, Alan B Sandler, David Miles, Robert L Coleman, Regula Deurloo, Olivier L Chinot. Cancer Treat Rev 2020